People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2017 |
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2011 |
| Therini Bio, Inc. | — | Biotechnology | Series C | $84.2M | $1.1B | 2023 |
Daniel D. Burgess at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel D. Burgess on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Patrick Heron | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Jonathan Leff | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Niall O'Donnell | 1 | 7 |
| Peter Moldt | 1 | 6 |
| Tracy Saxton | 1 | 5 |
| Scott M. Rocklage | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Steve Elms | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| A. Bruce Montgomery | 1 | 3 |
| Michael J. Kamdar | 1 | 3 |
| Kevin Judice | 1 | 3 |
| Richard G Vincent | 1 | 3 |
| Kevin Forrest | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.